---
title: "688176.SH (688176.SH) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/688176.SH/news.md"
symbol: "688176.SH"
name: "688176.SH"
parent: "https://longbridge.com/zh-CN/quote/688176.SH.md"
datetime: "2026-03-10T19:59:25.971Z"
locales:
  - [en](https://longbridge.com/en/quote/688176.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688176.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688176.SH/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/688176.SH/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/688176.SH/news.md)


# 688176.SH (688176.SH) — 相关新闻

### [Xiwei's approval ignites stock price, the losses and commercialization challenges behind Asieris' market value of 10 billion](https://longbridge.com/zh-CN/news/278394753.md)
*2026-03-09T12:47:04.000Z*
> Asieris launched the world's first non-invasive treatment product for Cervical Intraepithelial Neoplasia grade 2 (CIN2),

### [Healthcare Industry Daily (03.08): Breakthroughs in Pharmaceutical Innovation](https://longbridge.com/zh-CN/news/278277902.md)
*2026-03-08T19:15:16.000Z*
> Asieris' APL-1702 (Xiwetai) has been approved for market launch, becoming the world's first non-invasive treatment produ

### [Asieris: There is uncertainty regarding the production, import timeline, and procedures related to Xiweiya®](https://longbridge.com/zh-CN/news/278089799.md)
*2026-03-06T11:42:01.000Z*
> Asieris announced that Xiweiya® is a drug produced overseas, and production, import, and sales can only take place after

### [Asieris: Stock trading shows abnormal fluctuations, and there are no undisclosed significant matters that should be disclosed](https://longbridge.com/zh-CN/news/278080149.md)
*2026-03-06T10:45:40.000Z*
> Asieris Pharmaceuticals issued a notice of unusual fluctuations, stating that the company's stock closed with a cumulati

### [The three major A-share indices turned positive collectively, innovative drugs rebounded, the Hang Seng Index rose nearly 3%, JD.com increased by over 7%, while crude oil and the shipping index plummeted](https://longbridge.com/zh-CN/news/278017749.md)
*2026-03-06T02:40:40.000Z*
> The three major A-share indices collectively turned positive, with the innovative drug sector rebounding, and JD.com ris

### [Innovative drugs see a collective surge again](https://longbridge.com/zh-CN/news/278126802.md)
*2026-03-06T08:25:08.000Z*
> On March 6th, the innovative drug sector performed strongly, with companies such as Asieris and RemeGen seeing significa

### [The three major A-share indices collectively closed higher, with over 4,200 stocks in the entire market in the green](https://longbridge.com/zh-CN/news/278041961.md)
*2026-03-06T07:08:46.000Z*
> 36Kr learned that the three major A-share indices closed higher, with the Shanghai Composite Index up 0.38%, the Shenzhe

### [Policy sets the tone for pillar industries! Overseas BD transactions surge, innovative drug sector skyrockets](https://longbridge.com/zh-CN/news/278032567.md)
*2026-03-06T05:57:17.000Z*
> On March 6th, the Hong Kong A-share innovative drug sector surged strongly, with the A-share innovative drug sector expe

### ["A-Share Focus" Policy signals boost, pharmaceutical sector rises, Asieris up 20% to the limit](https://longbridge.com/zh-CN/news/278022047.md)
*2026-03-06T03:26:00.000Z*
> Under the boost of policy signals, the pharmaceutical sector performed strongly, with Asieris' stock price rising 20% to

### [](https://longbridge.com/zh-CN/news/278014813.md)
*2026-03-06T02:09:15.000Z*
> The A-share innovative drug sector continues to rise, Asieris hits a 20% limit up, BeBetter Med, SHANGHAI YIZHONG, Hotge